The Frontier
Op-eds, field notes, dispatches, and reading lists from the Sareen Lab — on cell therapy, biomanufacturing, and the science of making living medicines real.
Views expressed here are solely those of Dhruv Sareen in his personal and academic capacity and do not reflect the positions of any affiliated institution or organization.
Stay current
The biologics industry solved scale through automation and process standardization. Cell therapy hasn't. Here's what it will take — and why it matters more than any single therapy.
Five papers and one report that shaped our thinking this quarter — on closed-loop bioreactor control, vascularized organoids, and what the Answer ALS dataset is finally starting to reveal.
Notes from the bench on what actually breaks when you move iPSC-to-islet differentiation from 125mL spinner flasks to stirred-tank bioreactors — and what we did about it.
Universal donor cell therapy is closer than most people think. The bottleneck isn't the biology anymore.